The Sclera pp 299-307 | Cite as

Treatment of Episcleritis and Scleritis

  • Maite Sainz de la Maza
  • Joseph Tauber
  • C. Stephen Foster


The treatment of episcleritis can usually be strictly supportive, although in some instances systemic nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated. Diffuse and nodular scleritis can usually be effectively treated in the same way, that is, with NSAIDs. If NSAID therapy fails, systemic corticosteroid therapy is indicated, provided there are no contraindications to this approach. If the scleritis continues to recur with each attempt to discontinue steroid therapy after 6 months of treatment, immunomodulatory therapy (IMT) or biologic response modifiers (BRM) should be considered. The same applies for patients who develop serious steroid-induced side effects. Patients with an established, potentially lethal systemic vasculitis as the cause of scleritis (e.g., polyarteritis nodosa or granulomatosis with polyangiitis (Wegener)), and patients with necrotizing scleritis, always require treatment with IMT or BRM.


Systemic Lupus Erythematosus Rheumatoid Arthritis Patient Juvenile Idiopathic Arthritis Systemic Lupus Erythematosus Patient Polyarteritis Nodosa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Watson PG, Hazleman DL, Pavesio C, Green WR. The sclera and systemic disorders. London: Butterworth Heinemann; 2004, Chap 12. p. 291.Google Scholar
  2. 2.
    Lyons CJ, Hakin KN, Watson PG. Topical flurbiprofen: and effective treatment for episcleritis? Eye. 1990;4:521.PubMedCrossRefGoogle Scholar
  3. 3.
    Fronert PP, Scheps FG. Long term follow up study of patients with periarteritis nodosa. Am J Med. 1967;43:8.CrossRefGoogle Scholar
  4. 4.
    Fauci AS. Vasculitis. In: Parker CW, editor. Clinical Immunology. Philadelphia: W.B. Saunders; 1980. p. 473–519.Google Scholar
  5. 5.
    McGavin DDM, Williamson J, Forrester JV, et al. Episcleritis and scleritis. Br J Ophthalmol. 1976;60:192.PubMedCrossRefGoogle Scholar
  6. 6.
    Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60:163.PubMedCrossRefGoogle Scholar
  7. 7.
    Jones P, Jayson MIV. Rheumatoid arthritis of the eye. Proc Royal Soc Med. 1973;66:1161.Google Scholar
  8. 8.
    Foster CS. Nonsteroidal anti-inflammatory and immunosuppressive agents. In: Lambert DW, Potter DE, editors. Clinical ophthalmic pharmacology. Boston: Little Brown; 1987. p. 173–92.Google Scholar
  9. 9.
    Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369.PubMedCrossRefGoogle Scholar
  10. 10.
    McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe lupus erythematosus. N Engl J Med. 1988;318:1423.PubMedCrossRefGoogle Scholar
  11. 11.
    Raizman MB, Sainz de la Maza M, Foster CS. Tectonic keratoplasty for peripheral ulcerative keratitis. Cornea. 1991;10:312.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Maite Sainz de la Maza
    • 1
  • Joseph Tauber
    • 2
  • C. Stephen Foster
    • 3
  1. 1.Clinical Institute of OphthalmologyHospital Clinic of BarcelonaBarcelonaSpain
  2. 2.Tauber Eye CenterKansas CityUSA
  3. 3.Massachusetts Eye Research and Surgery InstitutionCambridgeUSA

Personalised recommendations